April 28th 2025
New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
Urologists show low adherence to value-based care pathway
May 13th 2017Urologists’ adherence to value-based care pathways for BPH surgery is extremely low and only modestly improved when given individualized feedback on patient outcomes, costs, and practice patterns relative to peers, say UCLA researchers.
Online information linked to PCa treatment regret
May 8th 2017Men who use the Internet as their primary source for prostate cancer treatment decision-making are more likely to regret those decisions a year after treatment than those whose primary sources of information are radiation oncologists or urologists.
Study: Consumer ads prompt men to seek TRT
May 4th 2017Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.
Most men prefer informed decision-making for PCa
April 28th 2017Participants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
Guidelines update: Bladder, kidney, prostate cancer
April 18th 2017This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
18F-choline PET/CT detects PCa recurrences early
April 15th 2017Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy (MDT), according to results of the screening phase of the phase II STOMP randomized trial.
Transgender surgery: Videos demonstrate cutting-edge techniques
In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.
Spacer system maintains QoL at 3 years post RT
March 23rd 2017Phase III study results suggest that a hydrogel spacer developed to separate the rectum and prostate during radiotherapy for prostate cancer works to maintain bowel and urinary quality of life and reduces late rectal toxicity by 78% at 3 years post radiotherapy.
Biomarkers predict metastasis, biochemical recurrence
March 22nd 2017Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Novel assay may help identify prostate Bx candidates
March 22nd 2017A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Hypofractionated IMRT outcomes comparable to standard regimen
March 20th 2017“We showed that we can safely compress radiation into a shorter time frame, into fewer treatments, at higher dose per fraction, with similar clinical outcomes and similar toxicity profiles,” said researcher Michael Wang, MD.
Testosterone therapy's big week: One urologist's perspective
March 16th 2017Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."
Testis Ca care deviates from guidelines in 30% of patients
March 1st 2017Nearly one-third of men with testicular cancer undergo diagnostic or therapeutic interventions that are at odds with guidelines from the National Comprehensive Cancer Network (NCCN), according a study published in the Journal of Urology (2017; 197:684-9).